New designs in early clinical drug development

Abstract

The availability of an unprecedented massive amount of data has provided a magnificent window of opportunity for the development of new drugs. There are currently more drugs in development targeting cancer than any other disease. While this has brought us new waves of drugs, the counterpart is that with these new molecules we have different mechanisms of action, drug kinetics and dynamics, response types and toxicity profiles, which impair classical early clinical trial designs from being effective and efficient. What we once treated as a 'one-size-fits-all' homogeneous disease, has now been uncovered to be a rather heterogeneous condition with multiple targetable mutations. As this generates endless scenarios, it will be impossible to design single 'me-too' trials for every different disease, target, biomarker and agent. To overcome this, we must focus on improving early phase studies, undoubtedly the most critical step from bench to bedside. Goals include decreasing clinical development times, lowering research and development costs and optimizing decisions in advancing through the several phases with a higher degree of certainty in exchange for less failed attempts. We need more informative and, really, transformative early phase designs that seek to obtain the typical late phase objectives in a time continuum and to allow for more robust and efficient go/no-go decisions. With this in mind, different classes of drugs seem to fit with different designs, which present solutions to the different challenges that they pose after finding the maximum tolerated dose/optimum biological dose. This article reviews these concepts and designs and how they can adapt to this new reality in early phase investigation.

Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice

“…Drug discovery and development represents an increasing economic and temporal cost for the pharmaceutical industry, which has not translated into significant increases in the number of approved active ingredients, especially in the oncology area [ 1 , 2 ]. One alternative is to develop mathematical models at the preclinical stages of the drug development process capable of better predicting efficacy or safety outcomes in order to efficiently design clinical trials [ 3 ].…”

Guidelines for clinical evaluation of anti‐cancer drugs

“…Rare cancers are a group of diseases with very few numbers of patients, which presents greater practical and therapeutic challenges than other cancers 68 . Among clinicopathologically defined (relatively common) cancers, rare subtypes are considered a group of diseases for which there is a common characteristic and biologically significant genomic alteration (such as a fusion gene, mutation, or gene amplification) that occur only in a very few patients 69 ; however, there is no clear definition of a rare subtype. It is not defined purely based on the estimated prevalence, and comprehensive analyses must be used to determine whether the target disease corresponds to a rare subset.…”

Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer

“…Indeed, the identification of biomarkers provides the possibility to use tumors and patient's characteristics to predict drug efficacy, guiding the treatment selection for each individual patient [20]. In particular, a validated predictive marker can prospectively identify individuals who are likely to have a positive clinical outcome, such as improved survival or decreased toxicity, from a specific treatment [21]. Moreover, targeted therapy has a toxicity profile significantly different from cytotoxic agents and typically results from target effects on normal tissues.…”